Tolero Pharmaceuticals to Present Positive Advancement of Clinical and Preclinical Programs at the American Association for Cancer Research 2015

SALT LAKE CITY, Utah--()--Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that Tolero and collaborators will present seven poster presentations scheduled at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, Pennsylvania, April 18-22, 2015. The presentations include clinical proof-of-concept data for alvocidib, a Phase III-ready CDK9 inhibitor for acute myeloid leukemia, as well as preclinical data for four of Tolero’s pipeline programs.

Details of the poster presentations are as follows:

Abstract: #3400
Title: Mitochondrial profiling in AML patients treated with an Alvocidib containing regimen reveals MCL1 dependency in responder bone marrow
Presenter: Elisha J. Dettman
Session Title: Development of Prognostic and Predictive Biomarker Assays
Session Category: Clinical Research
Presentation Time: Tuesday, April 21, 2015, 8:00 AM - 12:00 PM
Location: Section 21
Poster Board Number: 21

Abstract: #2698
Title: Combination strategies to target super enhancer transcriptional activity by CDK9 and BRD4 inhibition in acute myeloid leukemia
Presenter: Brigham L. Bahr
Session Title: Resistance to Pathway-Targeted Therapeutics 1
Session Category: Experimental and Molecular Therapeutics
Date: Monday, April 20, 2015, 1:00 PM – 5:00 PM
Location: Section 33
Poster Board Number: 20

Abstract: #3604
Title: Targeting the PIM kinases in combination with BTK inhibition is synergistic in preclinical models of B-cell malignancies
Presenter: Jeremiah J. Bearss
Session Title: Resistance to Pathway-Targeted Therapeutics 2
Session Category: Experimental and Molecular Therapeutics
Presentation Time: Tuesday, Apr 21, 2015, 8:00 AM -12:00 PM
Location: Section 31
Poster Board Number: 27

Abstract: #3647
Title: Targeting cancer-induced anemia with hepcidin lowering ALK2 inhibitors
Presenter: Peter W. Peterson  
Session Title: Drug Discovery: Kinases, Nuclear Hormone Receptors, and Novel Targets
Session Category: Chemistry
Presentation Time: Tuesday, April 21, 2015, 8:00 AM - 12:00 PM
Location: Section 34
Poster Board Number: 10

Abstract: #3586
Title: The use of kinome profiling to determine potential resistance pathways in pancreatic cancer cells treated with PIM kinase inhibitors
Presenter: Antonio T. Baines
Session Title: Resistance to Pathway-Targeted Therapeutics 2
Session Category: Experimental and Molecular Therapeutics
Presentation Time: Tuesday, April 21, 2015, 8:00 AM - 12:00 PM
Location: Section 31
Poster Board Number: 9

Abstract: #3579
Title: Identification of biomarkers of AXL-mediated drug resistance in head and neck squamous cell carcinoma
Presenter: Kavitha Balaji
Session Title: Resistance to Pathway-Targeted Therapeutics 2
Session Category: Experimental and Molecular Therapeutics
Presentation Time: Tuesday, April 21, 2015, 8:00 AM - 12:00 PM
Location: Section 31
Poster Board Number: 2

Abstract: #4096
Title: Identification of EMT inhibitors using novel zebrafish reporter lines
Presenter: Laura Jimenez
Session Title: Cancer Stem Cells and Epithelial-Mesenchymal Transition
Session Category: Tumor Biology
Presentation Time: Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM
Location: Section 16
Poster Board Number: 17

About Tolero
Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control. www.toleropharma.com

Contacts

Tolero Pharmaceuticals, Inc.
Joe Nilson, 801-285-6003
bizdev@toleropharma.com

Contacts

Tolero Pharmaceuticals, Inc.
Joe Nilson, 801-285-6003
bizdev@toleropharma.com